Levodopa-induced dyskinesia in Parkinson's disease: Insights from cross-cohort prognostic analysis using machine learning

Parkinsonism Relat Disord. 2024 Sep:126:107054. doi: 10.1016/j.parkreldis.2024.107054. Epub 2024 Jul 4.

Abstract

Background: Prolonged levodopa treatment in Parkinson's disease (PD) often leads to motor complications, including levodopa-induced dyskinesia (LID). Despite continuous levodopa treatment, some patients do not develop LID symptoms, even in later stages of the disease.

Objective: This study explores machine learning (ML) methods using baseline clinical characteristics to predict the development of LID in PD patients over four years, across multiple cohorts.

Methods: Using interpretable ML approaches, we analyzed clinical data from three independent longitudinal PD cohorts (LuxPARK, n = 356; PPMI, n = 484; ICEBERG, n = 113) to develop cross-cohort prognostic models and identify potential predictors for the development of LID. We examined cohort-specific and shared predictive factors, assessing model performance and stability through cross-validation analyses.

Results: Consistent cross-validation results for single and multiple cohort analyses highlighted the effectiveness of the ML models and identified baseline clinical characteristics with significant predictive value for the LID prognosis in PD. Predictors positively correlated with LID include axial symptoms, freezing of gait, and rigidity in the lower extremities. Conversely, the risk of developing LID was inversely associated with the occurrence of resting tremors, higher body weight, later onset of PD, and visuospatial abilities.

Conclusions: This study presents interpretable ML models for dyskinesia prognosis with significant predictive power in cross-cohort analyses. The models may pave the way for proactive interventions against dyskinesia in PD by optimizing levodopa dosing regimens and adjunct treatments with dopamine agonists or MAO-B inhibitors, and by employing non-pharmacological interventions such as dietary adjustments affecting levodopa absorption for high-risk LID patients.

Keywords: Cross-cohort analysis; Levodopa-induced dyskinesia; Longitudinal cohorts; Machine learning; Predictive modeling; Prognosis.

MeSH terms

  • Aged
  • Antiparkinson Agents* / adverse effects
  • Cohort Studies
  • Dyskinesia, Drug-Induced* / etiology
  • Female
  • Humans
  • Levodopa* / administration & dosage
  • Levodopa* / adverse effects
  • Longitudinal Studies
  • Machine Learning*
  • Male
  • Middle Aged
  • Parkinson Disease* / drug therapy
  • Prognosis

Substances

  • Levodopa
  • Antiparkinson Agents